Meloxicam injection (Anjeso) approved in US for management of moderate to severe pain alone or in combination with other non-NSAID analgesics
The approval for this once daily intravenous COX-2 preferential NSAID is supported by data from three Phase III studies showing reduced pain vs placebo in patients who underwent surgeries, including hip and knee replacements, abdominoplasty and bunionectomy.
Source:
Biospace Inc.